December 2016

Candidate Name: Magali Taiel-Sartral

Address: Waardstraat 12, 2315 KN Leiden, The Netherlands Phone: + 31 6 15 32 21 10 (m) Personal email: taielmagali@gmail.com Professional email: mtaiel@proqr.com

https://www.linkedin.com/profile/public-profile-settings?trk=prof-edit-edit-public_profile

MD/Ophthalmologist - 13 years clinical practice

17 years Pharmaceutical Industry experience in Research & Development and Medical Affairs

across a broad range of therapy areas encompassing Cardiovascular, Ophthalmology,

Rheumatology, Intensive Care, Urology, Sexology, Rare Diseases (Pulmonary Arterial Hypertension

[PAH], Duchenne Disease, Sickle Cells Disease), Diabetes.

International Positions for 12 years

Strong expertise in drug development and Global Clinical trials management and implementation, which includes: -Medical Oversight of Global clinical studies Phase II and III -Medical Lead for Regulatory interactions with European Medical Agency (EMA) Extensive Medical Affairs experience including:

-Medical Lead for Global clinical studies Phase IIIb-IV and Health Outcome (HO) studies -Medical Lead for Market Access and Reimbursement strategy, interactions with payers, dossiers authoring for several products in European countries -Medical Lead for Launch strategy and implementation: 5 Launches, with launch preparation, support to regulatory activities, writing of Market Access files, launch and post launch activities I have participated in the design of 9 protocols, in 21 studies implementation and execution I have authored 30 manuscripts and 43 abstracts Strong team management experience for 10 years:

-Up to 11 direct reports (Medical Doctors, Pharmacists, Scientists PhD, and Veterinary, working as Clinical Research Physicians [CRPs], Clinical Research Scientists [CRS], Medical Liaisons [ML] and Medical Affairs Professional [MAP]) -Across the Region (Europe)

Strong international line and matrix leadership experience with proven ability to engage multi-

function team members.

Excellent interpersonal and communication skills with track record of developing and

managing strong relationships with Investigators, Thought Leaders (TLs), conducting International

Advisory Boards (ABs) and Scientific Steering Committees, working with Advocacy groups and

experienced Alliance Manager.

Lead Advocacy Groups interactions and partnerships, role of Chief Patient Officer

December 2016

CAREER TO DATE

Industry Experience

PROQR THERAPEUTICS: Aug 2016 – Date

VP CLINICAL DEVELOPMENT - OPHTHALMOLOGY

LILLY FRANCE: 2004 - 2016

REGIONAL MEDICAL THERAPEUTIC AREA LEAD: 2013 - Aug 2016 CARDIOVASCULAR and RHEUMATOLOGY - FRANCE/BELGIUM/NETHERLANDS 5 molecules: Forsteo, Efient, Reopro, Evacetrapib, PCSK9 Ab – Reporting to Regional Senior Medical Director Supervision: 5 people (CRP, ML, CRSs, MAP) International clinical studies: Phase II and III (Evacetrapib, PCSK9 Ab, Efient Pediatric Sickle cells disease), Phase IIIb-IV (Forsteo, Efient), HO studies (Osteoporosis, Myocardial Infarction) Lead Advocacy Groups’ partnership from 2012, to improve clinical research effectiveness for the best benefit and quality of life of the patients, resulting in: -Concrete actions implemented in Lilly clinical trials over 2013/2014/2015. -External network with Minister of Health, Pharma trade association, Policy Makers, experts investigators, Ethic Committees, Academic Research Organizations (ARO), Clinical Research Organizations (CRO) Chairman at Regional and National ABs Maintain access: renewal of reimbursement dossiers Alliance Medical Manager: Daiichi Sankyo (DS) (Efient) Participation in Working Groups with Pharma Trade Industry, University Experts and other Pharmaceutical Companies: -Organization of the 2015 International R&D dating: “From Rare Diseases to Personalized Medicine”; -Organization of the 2015 International Biotech R&D dating MEDICAL DEPARTMENT LEAD: 2010 - 2013 CARDIOVASCULAR, RHEUMATOLOGY, INTENSIVE CARE, UROLOGY - FRANCE 7 molecules: Forsteo, Efient, Reopro, Xigris, Adcirca, Cialis, Axiron - Reporting to Medical Director Supervision: 6 people (CRPs, MLs, CRSs) International clinical studies: Phase III and IIIb-IV (Efient, Cialis, Forsteo, Adcirca), HO studies (Osteoporosis, Urology/Sexology, Myocardial Infarction, Acute Coronary Syndrome [ACS]) Medical Lead for 3 launches: Efient (ACS), Cialis (Benign Prostatic Hyperplasia), Adcirca (PAH) Issues management: Management of Xigris withdraw from the market Chairman at National ABs Alliance Medical Manager: DS (Efient); GSK (Adcirca) Participation in Cardiovascular Emergency Calls 24/7 Participation in Working Groups with Pharma Trade Industry, University Experts and other Pharmaceutical Companies (Private/Public Partnerships) EUROPE MEDICAL THERAPEUTIC AREA LEAD: CARDIOVASCULAR 2006 - 2010 2 molecules: Efient, Reopro - Reporting to Europe Medical Director Supervision: 11 people (CRPs, MLs, CRSs) Countries: Italy, UK, France, Sweden, Finland, Switzerland, Netherlands, Germany, Austria, Poland

International Clinical Studies: Phase III-IIIb-IV and HO studies (Myocardial Infarction, ACS): Protocols design and implementation, data analyses and release, publications Contribute to the clinical global development, build European Medical Plan Chairman at Scientific Steering Committees Protocols and CSR writing (ACAPULCO study, APTOR study) Chairman at Global, European and National ABs

December 2016

Efient Compassionate use for France: In 2009, I led the Efient Compassionate use program, set-up criteria for compassionate use by discussing with TLs, built the French dossier by interacting with the local Regulatory Agency and gained endorsement from the Global Alliance Lilly&DS. I managed the data collection, the interactions with physicians and the local Regulatory Agency along with affiliate Stakeholders. This was the unique compassionate use worldwide; as reported by clinicians, the availability of the medication saved ACS patients. Efient Market Access and Reimbursement for France and Belgium: France and Belgium Efient access files authoring, Presentation to France and Belgium authorities Assure coherence and alignment of Medical Liaison function between countries, all over Europe, Define and implement adequate Medical Liaisons metrics Coordinate internal training Lead the European medical information dissemination and assure coherence throughout Europe Alliance Medical Manager: DS (Efient) Participation in Cardiovascular Emergency Calls 24/7 MEDICAL THERAPEUTIC AREA LEAD - FRANCE/BELGIUM: INTENSIVE CARE 2004 - 2006 1 molecule: Xigris - Reporting to Europe Medical Director Xigris Market Access and Reimbursement for Belgium: Presentation to the Belgium authorities, dossier writing International Phase III, IIIb-IV and HO studies: Protocols implementation, data analyses and release, publications CSR writing (HO Belgium study) Medical Lead for Xigris Launch Chairman at France and Belgium ABs Chairman at Scientific Steering Committees PFIZER 2001 - 2004 MEDICAL ADVISOR - FRANCE: OPHTHALMOLOGY 3 molecules: Xalatan, Xalacom (Glaucoma), Macugen (Anti VEGF for neovascular age-related macular degeneration)

Registration files: Signed statements obtained from KOLs, collaboration with Global Medical and Europe Regulatory teams Market Access file Authoring Medical Lead for Xalacom Launch Phase IIIb and IV and HO studies: protocols design and implementation, data analyses and release, publications Protocols and CSRs writing Chairman at National Advisory Boards Chairman at Scientific Steering Committees for studies SERVIER 1999 - 2001 R&D INTERNATIONAL PROJECT MANAGER: RHEUMATOLOGY, DIABETOLOGY Centralized Coordination of multicentric, international phase II and III studies from Headquarter. Collaboration with the affiliates (Australia, New Zealand and Eastern Europe...).

Medical Experience/Ophthalmologist

Private Practice Experience: Private practice in Ophthalmology in Paris 1998 - 1999

Surgical practice/Photocoagulation/Retinal Angiography in clinic

Assistant Professor: Ophthalmology, Orléans 1995 - 1998 Standing in for the ophthalmology department head Surgical practice: one day weekly In charge of Interns management and training Paris Hospital Internship: 1990 - 1995 Ophthalmology: 4 years / Stomatology / Medical and Surgical Emergency

Academic Hospital: 1998 - 2012

Retinal analysis by Optical Coherence Tomography (1/2 day / week)

December 2016

Additional information

Languages: French native; English fluent It Skills: Power Point, Excel and Word Teaching Activities: Training and Management of University Students

2011: 1 student in Master of Sciences and Technology - 2nd Year (Master 2) - Integrative Biology and Physiology - Clinic and Experimental Pharmacology; Paris University; Training Report supervision Result: Validation of 2nd Year (Master 2) 1 student in one year training post PhD; Unit: Urology Result: Moving to Lilly recruitment at the end of the training period 2012: 1 student in Health Sciences and Technology License - 2nd Year (License 2) Zoom on Medical Department in Lilly France; University Bordeaux Segalen Result: Validation of 2nd Year (License 2) 2013: 1 student in Marketing school - ESG CI; 3 month-training in Medical, Marketing and Communication Departments Key Lectures at Conferences and Scientific Societies Congresses - From 2010

Lecture at the National ICs congresses

2010 - 2011: On behalf of the Alliance Lilly&DS: 250 attendees: ICs

Lecture at the Society of Emergency Physicians congresses

2010 - 2015: On behalf of the Alliance Lilly&DS: 200 attendees: Emergency Physicians

Lecture at Academic Conference: “The patient in the heart of the Clinical Research” 2014: On behalf of the Pharma Trade Association: 300 attendees : Investigators, Presidents of Ethic

Committees, GMs of CROs, Presidents of AROs, GMs of Academic Hospitals, Study Coordinators. Lecture at Lilly Advocacy Groups Days seminars 2013: “My treatment & I: From Clinical Research to Real Life”: 200 attendees 2014: “New Value of Medical Innovation”: 200 attendees

Lecture at seminars:

2011:”CV current and future challenges”: 250 attendees

2012: Present Eli Lilly new organization, 2012 priorities and strategic projects: 250 attendees 2013: Deliver training to affiliate on “Regulatory/Compliance requirements for Medical Meeting”: 150 attendees

EDUCATION

1990: Paris Hospital Intern Competitive Examination to access residency

1993: Medical Doctor Degree, Lariboisière Saint Louis University, Paris Thesis: "Diagnostic value of fundus examination in familial adenomatous polyposis". A. Tiret, M. Sartral, E. Tiret, L. Laroche. Br.J.Ophthalmol, 1997, 81: 755-758. Saint Antoine Hospital – Paris 1993: Ophthalmologist degree Post Graduate Dissertation: “Vitrectomy - photocoagulation - gas injection to treat congenital optic nerve pit associated with macular retinal detachment. M. Sartral, G. Mimoun, A. Glacet-Bernard, T. Delayre, G. Coscas. J.Fr.Ophtalmol, 1996, 19, 10, 603-609. Creteil University Clinic - Paris. 1994 - 1995: Courses in Statistic applied to clinical research: CESAM

Publications: See attached list

December 2016

APPENDIX: PUBLICATIONS

Publications during Clinical Practice

1996

1 Manuscript in French Journal of Ophthalmology - Impact Factor: 0.443: Vitrectomy-laser-gas for treating optic disk pits complicated by serous macular detachment. Vitrectomie - laser - gaz pour le traitement des fossettes colobomateuses de la papille compliquées de décollement séreux rétinien maculaire. M.Sartral, G.Mimoun, A.Glacet-Bernard, T.Delayre, G.Coscas. J.Fr.Ophtalmol, 02/1996; 19(10):603-9. Creteil University Clinic - Paris.

2 French Society of Ophthalmology: « Un cas de vasculite rétinienne tuberculeuse ». Poster. Uveitis.F.Tardy-Campinchi, M.Sartral, A.Erginay, M.Pâques, J.M.Salord, A.Gaudric. Lariboisière Hospital.

3 Medicine Society of Loiret: « Evaluation de l'acuité visuelle du sujet âgé en centres de moyen séjour et en maisons de retraite». Poster. M.Sartral, P.Nounou, D.Cohen. Orléans Hospital.

1997

4 Manuscript in British Journal of Ophthalmology - Impact Factor: 2.81: « Diagnostic value of fundus examination in familial adenomatous polyposis ». A.Tiret, M.Sartral, E.Tiret, L.Laroche. Br.J.Ophthalmol, 10/1997; 81(9):755-8. DOI:10.1136/bjo.81.9.755.Saint Antoine Hospital - Paris

5 French Society of Ophthalmology: « Acuité visuelle et causes de mauvaise vision en maisons de retraite ». Oral presentation and poster. Low vision. M. Sartral, P. Nounou, D. Cohen. Orléans Hospital.

6 French Society of Ophthalmology: « Bilan étiologique des uvéites : étude rétrospective portant sur 45 patients ». Oral presentation. Eye and general diseases. P.Nounou, D.Cohen, M.Sartral. Orléans Hospital

7 International Society of French Language for Visual Exploration: « Fundus Flavimaculatus: Forme à transmission dominante. A propos d’une famille ». Oral presentation. S.Majzoub, M.Sartral, M.P.Delplace, H.Semin. Tours Hospital.

1998

8 French Society of Ophthalmology: « Prévalence du handicap visuel dans une population de consultants en ophtalmologie générale hospitalière : résultats préliminaires ». Poster. D.Cohen, M.Sartral, P.Nounou, D.Moni, D.Simionescu, M.Hamar, M.E.Drouard. Orléans Hospital.

9 French Society of Ophthalmology: « Pseudo-tumeur inflammatoire de l’orbite de forme scléro-fibreuse : aspect clinique et évolutif, apport de l’histologie ». Oral presentation and poster. Pseudo-tumors. D.Simionescu, M.Sartral, P.Nounou, D.Dorling-Carter, P.Michenet, D.Cohen. Orléans Hospital.

10 French Society of Ophthalmology: « Fundus flavimaculatus: forme à transmission dominante. A propos d’une famille ». Poster. Pigmentary retinopathy. S.Majzoub, M.Sartral, M.A.Delplace, F.Bourcier. Tours Hospital, Orléans Hospital.

11 French Society of Ophthalmology: « Neuropathie optique et mucormycose rhino-cérébrale: à propos d’une observation ». Poster. Infectious diseases. M.Dewaele, D.Simionescu, P.Nounou, M.Sartral, D.Dauphin, S.Sire, D.Cohen. Orléans Hospital.

1999

12 Manuscript in French Journal of Ophthalmology - Impact Factor: 0.443: Visual acuity and ocular diseases in aged residents of nursing homes: study of 219 persons in Orléans. « Acuité visuelle et pathologie oculaire chez le sujet âgé résidant en maison de retraite: étude orléanaise sur 219 personnes ». M.Sartral, P.Nounou, C.Rea, A.El Alamy, K.Bendeddouche, M.Boumezrag, R.Milcamps, D.Cohen. J.Fr.Ophtalmol, 05/1999; 22(4):431-7. Orléans Hospital.

13 French Society of Ophthalmology:« Récupération visuelle après chirurgie du décollement de rétine non compliqué : étude sur 59 patients ». Oral presentation. Retinal detachment.M.L.Lelez, P.Nounou, M.Sartral, D.Cohen. Orléans Hospital.

December 2016

14 French Society of Ophthalmology:« Vasculite rétinienne occlusive et résistance à la protéïne C activée : à propos d’une observation ». Poster. Retina. M.Dewaele, M.Sartral, E.Legac A.Charenton, M.Ranguin, D.Cohen. Orléans Hospital

2000

15 Manuscript in French Journal of Ophthalmology - Impact Factor: 0.443. Evaluation of moderate and severe visual impairments in patients attending an ophthalmology clinic. A prospective study of 1,172 patients. Journal Français d’Ophtalmologie 06/2000; 23(5):437-43. D Cohen, M Sartral, P Nounou, M Hamar, M E Drouard, A El Alamy, K Bendeddouche

. · Publications during Industry Experience

2002

16 French Society of Ophthalmology:« Glaucome et hypertonie oculaire : Importance de la pression intraoculaire (PIO) cible dans la prise en charge thérapeutique en France. Glaucoma and ocular hypertension: Is the target intraocular pressure the main objective in the treatment strategy in France? ». Oral presentation. Glaucoma. A.Bron (Dijon), JP. Nordmann (Paris), C. Baudouin (Paris), JF. Rouland (Lille), A. Kadi, M.Sartral (Pharmacia).

2003

17 French Society of Ophthalmology:« Prévalence d’une hypertonie oculaire et du glaucome dans une population française d’âge moyen, non sélectionnée. Prevalence of intra-ocular hypertension and open angle glaucoma in a non-selected middle-aged French population ». Oral presentation. Glaucoma. A.Bron (Dijon), C. Baudouin (Paris), JP. Nordmann (Paris), JF. Rouland (Lille), F. Thomas, K. Bean, B. De Clercq, A. Benetos, A. Coscas (Centre d’Investigations Préventives et Cliniques - Paris).

18 Manuscript in French Journal of Ophthalmology - Impact Factor : 0.443:« Glaucome et hypertonie oculaire : Importance de la pression intraoculaire (PIO) cible dans la prise en charge thérapeutique en France. Glaucoma and ocular hypertension: the importance of intraocular pressure in treatment decisions in France. ». A.Bron (Dijon), JP. Nordmann (Paris), C. Baudouin (Paris), JF. Rouland (Lille), A. Kadi, M.Sartral (Pharmacia). J.Fr.Ophtalmol, 2003; 26, 9: 895 - 903.

2004

19 French Society of Ophthalmology:« Etude de la réduction de la pression intraoculaire (PIO) et de la symptomatologie sous latanoprost, chez des patients présentant un glaucoma primitif à angle ouvert (GPAO) ou une hypertonie oculaire (HTO) ». M. Sartral (Pfizer), C. Baudouin (Paris), JF. Rouland (Lille), JP. Nordmann (Paris), A. Bron (Dijon).

20 French Society of Ophthalmology:« Enquête observationnelle sur les conditions d'utilisation des bithérapies dans le traitement de seconde intention de l'hypertonie oculaire (HTO) ou du glaucome à angle ouvert (GAO) en France ». A. Bron (Dijon), JP. Nordmann (Paris), JF. Rouland (Lille), C. Baudouin (Paris), M. Sartral (Pfizer).

21 French Society of Ophthalmology:« Enquête Française Glaucome et Hypertonie 1 Jour (EFGH1J) ». M. Villain (Montpellier), JP. Nordmann (Paris), JP. Renard (Paris), A. Bron (Dijon), F. Pelen, M. Sartral (Pfizer), C. Delcourt (Montpellier).

22 Manuscript in French Journal of Ophthalmology - Impact Factor : 0.443:« Prévalence de l’hypertonie oculaire et du glaucome dans une population française non sélectionnée. Prevalence of intra-ocular hypertension and glaucoma in a non-selected French population ». A.Bron (Dijon), C. Baudouin (Paris), JP. Nordmann (Paris), JF... Rouland (Lille), M. Sartral (Pfizer), F. Thomas, K. Bean, B. De Clercq, A. Benetos, A. Coscas (Centre d’Investigations Préventives et Cliniques - Paris).

23 European Society of Intensive Care Medicine (ESICM) - October 2004: « Monitoring of sepsis-induced immunoparalysis by measuring monocytic HLA-DR in septic shock ». A. Lepape (Lyon), N. Voirin, P. Vanhems, A.L. Debard, J. Bohe, J. Bienvenu, G. Monneret

2005

24 Society of French Language for Intensive Care (SRLF) - January 2005: « Exploration of Drotrecogin Alfa (Activated) in Adult Patients with Severe Sepsis at Lower Risk of Death ». P.F.

December 2016

Laterre (Brussels), J. Carlet (Paris), D. Payen (Paris), R. Garg (Lilly), M. Sartral (Lilly), E. Abraham (Denver US).

25 European Society of Intensive Care Medicine (ESICM) - September 2005: « Analysis of Drotrecogin Alfa (Activated) use in Belgian ICUs: Comparison to Progress Registry Data ». J.L Vincent (Brussels), P.F. Laterre (Brussels), J. Janes (Lilly), D. Nelson (Lilly), T. Haentjens (Lilly), M. Sartral (Lilly), M. Ermens (Lilly).

2006

26 Society of Critical Care Medicine (SCCM) - January 2006:« 90-day follow-up of patients treated with Drotrecogin Alfa (Activated) (DAA) for severe sepsis: Belgian open label study».J.Decruyenaere (Ghent), D. De Backer (Brussels), H. Spapen (Brussels), P-F. Laterre (Brussels), J. Raemaekers (Wilrijk), P. Rogiers (Antwerpen), H. Trine (Haine Saint-Paul), T. Haentjens (Lilly), M. Sartral (Lilly), T. Wagner (Lilly).

27 Society of French Language for Intensive Care (SRLF) - January 2006: « Vascular properties of APC in an endotoxin shock model ». O Desebbe (Nancy); N Sennoun (Nancy); S Gibot (Nancy); B Levy (Nancy).

28 Manuscript in Intensive Care Medicine - Impact Factor: 5.258: « Cardiovascular protective role for activated protein C during endotoxemia in rats ». R. Favory (Lille), S. Lancel (Lille), X. Maréchal (Lille), S. Tissier (Lille), R. Neviere (Lille).Intensive Care Medicine, 2006; 32: 899 - 905.

29 Manuscript in Intensive Care Medicine - Impact Factor: 5.258:« Persisting low monocyte HLA-DR expression predicts mortality in septic shock ». G. Monneret (Lyon), A. Lepape (Lyon), N. Voirin (Lyon), J. Bohé (Lyon), F. Venet (Lyon), Anne-Lise Debard (Lyon), H. Thizy (Lyon), J. Bienvenu (Lyon), F. Gueyffier (Lyon), P. Vanhems (Lyon).Intensive Care Med, 2006; 32: 1175 - 1183.

30 European Society of Intensive Care Medicine (ESICM) - September 2006: « Effects of Xigris on plasma and lung cytokines concentrations in oleic-induced acute lung injury ». F. Bregeon (Marseille), J-C. Richard (Lyon), V. Leray (Lyon), D. Le Bars (Lyon), N. Costes (Lyon), C. Tourvieille (Lyon), F. Lavenne (Lyon), G. Gimenez (Lyon), C. Guerin (Lyon).

31 European Society of Intensive Care Medicine (ESICM) - September 2006: « Effects of Xigris on the distribution of regional pulmonary blood flow and aerated lung volume in oleic-induced acute lung injury. A pet study. ». J-C. Richard (Lyon), F. Bregeon (Marseille), V. Leray (Lyon), D. Le Bars (Lyon), N. Costes (Lyon), C. Tourvieille (Lyon), F. Lavenne (Lyon), G. Gimenez (Lyon), C. Guerin (Lyon).

32 Manuscript in French Journal of Ophthalmology - Impact Factor: 0.443. Observational survey on the use of dual therapy in ocular hypertension or glaucoma treatment. Journal francais d'ophtalmologie 03/2006; 29(2):164-8. A Bron, J-P Nordmann, J-F Rouland, C Baudouin, M Sartral

33 Manuscript in French Journal of Ophthalmology - Impact Factor: 0.443. Article: Enquête observationnelle sur les conditions d’utilisation des bithérapies dans le traitement de l’hypertonie oculaire ou du glaucome à angle ouvert en France Journal Français d’Ophtalmologie 02/2006; 29(2):164-168. DOI:10.1016/S0181-5512(06)73765-2. A. Bron, J.-P. Nordmann, J.-F. Rouland, C. Baudouin, M. Sartral

2007

34 French Society of Pharmacology - January 2007: « Beneficial hemodynamic effects of activated protein c in a rodent model of endotoxic shock ». Oral Presentation.R. Favory (Lille), S. Lancel (Lille), R. Neviere (Lille), A. Durocher (Lille).

35 Manuscript in Intensive Care Medicine - Impact Factor: 5.258 - Accepted in June 2007: « Effects of Activated C Protein on regional pulmonary blood flow and cytokine production in experimental acute lung injury. ». J-C. Richard (Lyon), F. Bregeon (Marseille), V. Leray (Lyon), D. Le Bars (Lyon), N. Costes (Lyon), C. Tourvieille (Lyon), F. Lavenne (Lyon), M. Devouassoux (Lyon), G. Gimenez (Lyon), C. Guerin (Lyon).

36 Manuscript in Shock - Impact Factor: 2.612 - Accepted in July 2007: “Endothelial glycocalyx damage during endotoxemia coincides with microcirculatory dysfunction and vascular oxidative stress “. X. Marechal (Lille), R. Favory (Lille), O. Joulin (Lille), D. Montaigne (Lille), S. Hassoun (Lille), B. Decoster (Lille), F. Zerimech (Lille), R. Neviere (Lille).

December 2016

37 French-speaking Congress of Interventional Cardiology - October 2007 - Paris: Une dose de charge de 60 mg de Prasugrel entraîne une meilleure inhibition plaquettaire, en comparaison à des doses de charge de 300 mg et 600 mg de Clopidogrel". Poster Presentation. J. Jakubowski (Lilly, Indianapolis, USA), M. Sartral (Lilly Critical Care Europe - Paris - France), C. Payne (Lilly, Windlesham, UK), Y. Li (Lilly, Indianapolis, USA), D. Salazar (Daiichi Sankyo, Parsippany, NJ, USA), D. Small (Lilly, Indianapolis, USA), N. Farid (Lilly, Indianapolis, USA), J. Brandt (Lilly, Indianapolis, USA), K. Winters (Lilly, Indianapolis, USA).

2008

38 Manuscript in Acta Clinica Belgica, 2008; 63-1 - Impact Factor: 1.194 «A registry of patients treated with Drotrecogin Alfa (Activated) in Belgian Intensive Care Units - An observational study». 01/2007; 63(1):25-30. DOI:10.1179/acb.2008.004 · J-LVincent, P-F Laterre, J Decruyenaere, H Spapen, J Raemaekers, F Damas, P Rogiers, M Sartral (Lilly), T Haentjens (Lilly), D Nelson (Lilly), J Janes (Lilly).

39 Manuscript in Value in Health - Impact Factor: 2.89. Health Care Resources and Quality of Life in Acute Coronary Syndrome patients in 2007: French baseline results from the Antiplatelet Treatment Observational Study (APTOR). Value in Health 11/2008; 11(6). DOI: 10.1016/S1098-3015(10)66382-6. J Ferrieres, S Tcherny-Lessenot, M Sartral, J Pentel, V Delahais

40 Manuscript in Value of Health - Impact Factor: 2.89. International comparison of health care resources and quality of life in acute coronary syndrome patients in 2007: Results from the antiplatelet treatment observational study (APTOR). Value in Health 05/2008; 11(3). DOI: 10.1016/S1098-3015(10)70664-1. A Bakhai, A Iniguez, J Ferrieres, N Needs, C Schmitt, M Sartral, U Zeymer

41 Society of French Language for Intensive Care (SRLF) January 2008: « Génération de microparticules portant l’EPCR dans le sepsis sévère traité par la drotrecogin alfa». Oral Presentation L Chimot, N Morel, HN Bui, F Vargas, G Hilbert, C Perdrix, C Clément, A Nurden, P Nurden (CRPP Centre de Référence des Pathologies Plaquettaires, Polyclinique Bordeaux Nord Aquitaine, CHU Hôpitaux de Bordeaux, Université Bordeaux 2)

42 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 2008 Congress - 13th International Meeting - Poster Presentation May 3, 2008: “International Comparison of Health Care Resources and Quality of Life in Acute Coronary Syndrome patients in 2007: Results from the AntiPlatelet Treatment Observational study (APTOR)”A. Bakhai (London, UK), A. Iniguez (Vio, Spain), J. Ferrieres (Toulouse, France), N. Needs (Lilly, UK), C. Schmitt (Lilly, UK), M. Sartral (Lilly, France), U. Zeymer (Ludwigshafen, Germany) on behalf of the APTOR investigators

43 Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2008 - Poster Presentation Apr 30, 2008: “Multinational comparison of health care use in Acute Coronary Syndrome patients undergoing PCI: Results from the AntiPlatelet Treatment Observational Registry (APTOR). A. Bakhai, A. Iniguez, J. Ferrieres, N. Needs, C. Schmitt, M. Sartral (Lilly), and U. Zeymer on behalf of the APTOR investigators.

44 European Society of Cardiology - September 2008 - ACAPULCO study: Abstract entitled “Prasugrel 10 mg provides greater platelet inhibition than clopidogrel 900/150 mg in UA/NSTEMI ACS - The ACAPULCO study” Oral Presentation during a State of the Art and Featured Research Session at the ESC Congress 2008 – Munich, Germany, 30 August - 3 September 2008.

45 European Society of Cardiology - September 2008 - Abstract - Oral Presentation: “Antiplatelet patterns of use in ACS patients undergoing PCI in 2007: results from APTOR” - J Ferrieres, A Bakhai, M. Sartral (Lilly).

46 European Society of Cardiology in September 2008 - Abstract - Poster Presentation: “Factors determining use of stents in patients presenting with acute coronary syndromes and undergoing PCI: results from APTOR” - Iniguez et al, M. Sartral (Lilly).

47 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - 11thAnnual European Congress - Abstract APTOR GPIIb/IIIa Results from the Antiplatelet Treatment Observational Registry (APTOR)” - Planned Jun 23, 2008 Nov 8, 2008 K Leidreiter et al (ML Coaching)

December 2016

48 French-speaking Congress of Interventional Cardiology - October 2008 - Paris: Abstract Management of Acute Coronary syndrome in 2007: French results from the AntiPlatelet Treatment Observational study (APTOR) Planned Jul 10, 2008 Oct 1, 2008 - J Ferrieres, M Sartral, J Pentel, S Tcherny-Lessenot.

49 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - Abstract Health Care Resources and Quality of Life in Acute Coronary Syndrome patients in 2007: French results from the AntiPlatelet Treatment Observational study (APTOR) International Society for Pharmacoeconomics and Outcomes Research (ISPOR) - 11th Annual European Congress Planned Jun 23, 2008 Nov 8, 2008 J Ferrieres, M Sartral, J Pentel, S Tcherny-Lessenot

2009

50 Manuscript in Acta Clinica Belgica, 2009; 64-1 - Impact Factor: 1.194 - « 90-day follow-up of patients treated with Drotrecogin Alfa (Activated) for severe sepsis: A Belgian open label study». Running title: «The BOOST-study with Drotrecogin Alfa (Activated) in severe sepsis». 12/2005; 64(1):16-22. DOI: 10.1097/00003246-200512002-00037. J. Decruyenaere (Ghent), D. De Backer (Brussels), H. Spapen (Brussels), P-F. Laterre (Brussels), J. Raemaekers (Wilrijk), P. Rogiers (Antwerpen), H. Trine (Haine Saint-Paul), M. Sartral (Lilly), T. Haentjens (Lilly), T. Wagner (Lilly).

51 Manuscript in “Revue d’Epidémiologie et de Santé Publique” - Impact Factor : 0.66 - Utilisation de ressources et qualité de vie des patients souffrant d’un syndrome coronarien aigu en 2007 : résultats français à l’inclusion de l’étude Antiplatelet Treatment Observational Study (APTOR) Revue d’Épidémiologie et de Santé Publique 10/2009; 57. DOI:10.1016/j.respe.2009.07.007. J. Ferrieres, S. Tcherny-Lessenot, D. Granados, F. Raguideau, M. Sartral

52 Manuscript in Value in Health - Impact Factor: 2.89 – Health Care Resources Utilization in Acute Coronary Syndrome patients one year after PCI: French results from the Antiplatelet Treatment Observational Registry (APTOR). Value in Health 10/2009; 12(7). DOI: 10.1016/S1098-3015(10)74687-8. J Ferrieres, S Tcherny, D Granados, M Sartral

53 Manuscript in Value in Health - Impact Factor: 2.89 - Practice Patterns and Quality of Life in Acute Coronary Syndrome patients in 2008: Czech Republic baseline results from the Antiplatelet Treatment Observational Registry II (APTOR II). Value in Health 10/2009; 12(7). DOI: 10.1016/S1098-3015(10)74557-5. Z Coufal, K Norrbacka, M Hronkova, MA Paget, M Sartral, C Schmitt

54 French Society of Cardiology - January 2009 - Abstract: “Antiplatelet Patterns of Use in Acute Coronary Syndrome Patients undergoing PCI in 2007: Results from the Antiplatelet Treatment Observational Registry (APTOR)”. J Ferrieres, M Sartral, J Pentel, S Tcherny-Lessenot (Lilly).

55 French Society of Cardiology - January 2009 - Abstract From clinical trial to clinical practice: Risk of bleeding in acute coronary syndrome patients undergoing PCI. Results from the Antiplatelet Treatment Observational Registry (APTOR) - U. Zeymer, A Bakhai, J Ferrieres, M Belger, C Schmitt, M Sartral, A Iniguez on behalf of the APTOR investigators.

56 French Society of Cardiology - January 2009 - Abstract: Multinational Comparison of Health Care Use in Acute Coronary Syndrome patients undergoing PCI: Results from the AntiPlatelet Treatment Observational Registry (APTOR).J Ferrieres, M Sartral, J Pentel, S Tcherny-Lessenot

57 European Society of Cardiology 2009 - Abstract: 12-month patterns of supportive therapies in acute coronary syndrome patients undergoing PCI in 2007-08: results from the Antiplatelet Treatment Observational Registry (APTOR) Ameet Bakhai, Andres Iniguez, Jean Ferrieres, Claude Schmitt, Magali Sartral, Mark Belger, Uwe Zeymer

58 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - October 2009 - 12thAnnual European Congress – Abstract Country-specific differences in 12-month patterns of antiplatelet use in ACS patients undergoing PCI in 2007-08: Results from the antiplatelet treatment observational registry (APTOR). Zeymer U, Ferrieres J, Iniguez A, Schmitt C, Sartral M, Belger M, Bakhai A

59 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - October 2009 - 12thAnnual European Congress - Abstract Practice patterns and quality of life in acute coronary syndrome patients in 2008: Czech Republic baseline results from the antiplatelet

December 2016

treatment observational registry II (APTOR II). Coufal Z, Norrbacka K, Hronkova M, Paget MA, Sartral M, Schmitt C

60 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - October 2009 - 12thAnnual European Congress – Abstract Healthcare resources utilization in acute coronary syndrome patients one year after PCI: French results from the antiplatelet treatment observational registry (APTOR) J Ferrieres, S Tcherny-Lessenot, D Granados, M Sartral

61 French-speaking Congress of International Cardiology - October 2009 - Paris - Society GACI and French Society of Cardiology - Abstract: Management of patients with Acute Coronary syndrome undergoing percutaneous coronary intervention: one year follow-up results from the French cohort in the AntiPlatelet Treatment Observational study (APTOR). J Ferrieres, M Sartral, J Pentel, S Tcherny-Lessenot

2010

62 French Society of Cardiology - January 2010 - Abstract: Management of patients with Acute Coronary syndrome undergoing percutaneous coronary intervention: one year follow-up results from the French cohort in the AntiPlatelet Treatment Observational study (APTOR) - Poster: European days of French society of cardiologists J Ferrieres, M Sartral, J Pentel, S Tcherny-Lessenot

63 Primary Manuscript in Current Medical Research and Opinion - Impact Factor: 2.498 - Posted online on August 2, 2010.Treatment patterns in patients with acute coronary syndrome undergoing percutaneous coronary intervention - 09/2010; 26(9):2193-202. DOI:10.1185/03007995.2010.509257 Jean Ferrieres, Ameet Bakhai, Andres Iñiguez, Claude Schmitt, Magali Sartral, Mark Belger, Uwe Zeymer, on behalf of the APTOR trial investigators

64 Manuscript in Archives of Cardiovascular Diseases Management of patients with acute coronary syndrome undergoing percutaneous coronary intervention: one year follow-up results from the French cohort in the AntiPlatelet Treatment Observational study Archives of Cardiovascular Diseases Supplements 01/2010; 2(1):10-10. DOI: 10.1016/S1878-6480(10)70032. Jean Ferrieres, Stephanie Tcherny-Lessenot, Denis Granados, Magali Sartral

65 European Society of Cardiology - August 2010 - Poster Presentation: Contemporary differences in antiplatelet patterns of use in ACS patients undergoing PCI between 2007-2009 from 14 countries: results from the Antiplatelet Treatment Observational Registry (APTOR). U. Zeymer, S. James, Z. Coufal, K. Norrbacka, M. Sartral, M-A. Paget, ME. Tomlin, J. Ferrieres, A. Bakhai

66 European Society of Cardiology - August 2010 - Poster Presentation: An international examination of the variations in the management pathway of ACS patients undergoing PCI: results from the Antiplatelet Treatment Observational Registry (APTOR). A. Mohacsi, G. Pavlides, G. Berkenboom, K. Norrbacka, J. Goedicke, M-A. Paget, ME. Tomlin, A. Bakhai

67 European Society of Cardiology - August 2010 - Poster Presentation: Constructing and validating a scoring model to determine a meaningful clinical improvement in quality of life for patients admitted with an ACS undergoing PCI. A. Bakhai, G. Pavlides, A. Iniguez, C. Schmitt, M. Sartral, M. Belger, ME. Tomlin, S. James

68 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - 2010: An international comparison of dual antiplatelet use by stent type at 6 months following hospital discharge after acute coronary syndrome: Results from the Antiplatelet Treatment Observational Registry II (APTOR-II) Pavlides, Coufal, Mohacsi, James, Zeymer, Paget, Goedicke, Norrbacka, Berkenboom

69 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - 2010: An international comparison of antiplatelet use at 6 months following hospital discharge in UA/NSTEMI and STEMI patients undergoing PCI: Results from the Antiplatelet Treatment Observational Registry II (APTOR-II)Coufal, Berkenboom, Pavlides, Mohacsi, James, Paget, Goedicke, Norrbacka, Zeymer

70 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - 2010: Practice patterns and Quality of Life in Acute Coronary Syndrome patients in 2008-2009: baseline results for Germany from the AntiPlatelet Treatment Observational Registry II (APTOR II) U Zeymer, K Norrbacka, M-A Paget, J Goedicke, J Clouth

December 2016

71 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - 2010: Practice patterns and Quality of Life in Acute Coronary Syndrome patients in 2008-2009: baseline results for Austria from the AntiPlatelet Treatment Observational Registry II (APTOR II) Ammer, Paget, Hronkova, Norrbacka, Eber

72 Manuscript in Thrombosis and Haemostasis - Impact Factor: 6.094 - Prasugrel compared with high-dose clopidogrel in acute coronary Syndrome The randomised, double-blind ACAPULCO study - Thromb Haemost 2010; 103: 213–223 - Gilles Montalescot; Georgios Sideris; Remy Cohen; Catherine Meuleman; Claire Bal dit Sollier2; Olivier Barthélémy; Patrick Henry; Pascal Lim; Farzin Beygui; Jean-Philippe Collet; Debra Marshall; Junxiang Luo; Helene Petitjean; Ludovic Drouet

2011

73 Manuscript in European Journal of Cardiovascular Prevention and Rehabilitation - Impact

Factor: 3.903: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology - International Data on Supportive Therapies at 1 Year in Acute Coronary Syndrome Patients Undergoing PCI: Results from the APTOR study. 2011 Jun; 18(3):518-25. doi: 10.1177/1741826710389382. Epub 2011 Feb 18. Ameet Bakhai, Jean Ferrieres, Andres Iñiguez, Claude Schmitt, Magali Sartral, Mark Belger, Uwe Zeymer, on Behalf of APTOR Study Investigators.

74 Manuscript in Eurointervention - Journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology - Impact Factor: 3.76 - Treatment Patterns in Acute Coronary Syndrome Patients in the United Kingdom Undergoing PCI 03/2011; 6(8):992-6. DOI: 10.4244/EIJV6I8A171. Ameet Bakhai, Andres Iñiguez, Jean Ferrieres, Claude Schmitt, Magali Sartral, Mark Belger, Uwe Zeymer, on Behalf of APTOR Trial Investigators.

75 Manuscript in Value in Health - Impact Factor: 2.89. Optimal Treatment Shortfalls and Worse 12Month Outcomes for Diabetic Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention in Contemporary Practice: Data from the Multinational, Prospective, Antiplatelet Treatment Outcomes Registry (APTOR) Value of Health 11/2011; 14(7). DOI:10.1016/j.jval.2011.08.731. S. James, A. Iniguez, G. Pavlides, U. Zeymer, M. Sartral, M. Belger, M. E. Tomlin, K. Norrbacka, A. Bakhai .

76 European Society of Cardiology - 2011: Abstract - Oral Presentation: Risk of cardiovascular and bleeding events and mortality in patients with chronic kidney disease and ACS undergoing PCI: Results from the APTOR-II study J. Ferrieres, G. Berkenboom, Z. Coufal, S. James, A. Mohacsi, G. Pavlides, K. Norrbacka, M. Sartral, M-A. Paget, U. Zeymer.

77 Manuscript in Archives of Cardiovascular Diseases - Impact Factor: 1.662, Available online 5 February 2011A prospective observational study of treatment practice patterns in acute coronary syndrome patients undergoing percutaneous coronary intervention in Europe - Une étude observationnelle prospective sur les schémas de prise en charge thérapeutique des patients avec un syndrome coronarien aigu traités par angioplastie coronarienne percutanée en Europe. Archives of Cardiovascular Disease 02/2011; 104(2):104-14. DOI:10.1016/j.acvd.2010.12.002. Jean Ferrières, Magali Sartral, Stéphanie Tcherny-Lessenot, Mark Belger, on behalf of APTOR trial investigators

78 Manuscript in Value in Health - Impact Factor: 2.89. Treatment and 12 Month Outcomes of Acute Coronary Syndromes Patients Aged < 75 and ≥ 75 Years Undergoing Percutaneous Coronary Intervention: 14Country Data on 4545 Patients from the Prospective Antiplatelet Treatment Outcomes Registry (APTOR). Value in Health 11/2011; 14(7). DOI:10.1016/j.jval.2011.08.733· G. Berkenboom, Z. Coufal, J. Ferrieres, A. Mohacsi, M. Sartral, M. Belger, M. E. Tomlin, K. Norrbacka, A. Bakhai.

79 Manuscript in European Journal of Cardiovascular Prevention and Rehabilitation - IF:

3.903: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology - Differences in the Use of Guideline Recommended Therapies among 14 European Countries in Patients with Acute Coronary Syndromes undergoing PCI. 2013 Apr; 20(2):218-28. doi: 10.1177/2047487312437060. Epub 2012 Jan 24. Uwe Zeymer, Stefan James, Guy Berkenboom, Attila Mohacsi, Andres Iñiguez, Zdeněk Coufal, Magali Sartral, Marie-Ange Paget, Kirsi Norrbacka, Jean Ferrieres, Ameet Bakhai, on Behalf of APTOR Investigators.

December 2016

80 Manuscript in General & clinical epidemiology CKD 1-5 (1) RISK. NDT Plus 01/2011; 4 (suppl 2). J Ferrières, G Berkenboom, Z Coufal, S James, A Mohácsi, G Pavlides, K Norrbacka, M Sartral, M A Paget, M Tomlin

81 AHA (American Heart Association) - 2011: Abstract: Poster Presentation. Predictors and Outcomes of Patients with Acute Coronary Syndrome who Receive Optimal Therapy: Results from the Antiplatelet Treatment Observational Registries (APTOR I and II)Uwe Zeymer, Guy Berkenboom, Zdenek Coufal, Mark Belger, Molly Tomlin, Magali Sartral, Kirsi Norrbacka, Walid Fakhouri Ameet Bakhai

82 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - 2011: Abstract: Oral Presentation. Predictors, Cost and Outcomes of Patients with Acute Coronary Syndrome who Receive Optimal Therapy: Results from the Antiplatelet Treatment Observational Registries (APTOR I and II). Uwe Zeymer, Guy Berkenboom, Zdenek Coufal, Mark Belger, Molly Tomlin, Magali Sartral, Kirsi Norrbacka, Walid Fakhouri Ameet Bakhai - Podium session: Assessing effect of medication adherence and persistence on cost-effectiveness.

83 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - 2011: Abstract: Poster Presentation. Optimal treatment shortfalls and worse 12-month outcomes for diabetic acute coronary syndrome patients after percutaneous coronary intervention in contemporary practice: Data from the multinational, prospective, Anti-Platelet Treatment Outcomes Registry (APTOR). S. James, A. Iniguez, G. Pavlides, U. Zeymer, M. Sartral, M. Belger, M. Tomlin, K.Norrbacka, A. Bakhai.

84 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - 2011: Abstract: Poster Presentation. Treatment and 12-month outcomes of acute coronary syndromes patients aged < 75 and ≥ 75 years undergoing percutaneous coronary intervention: 14 country data on 4545 patients from the prospective Anti-Platelet Treatment Outcomes Registry (APTOR) G. Berkenboom, Z. Coufal, J. Ferrieres, A. Mohacsi, M. Sartral, M. Belger, M. Tomlin, K.Norrbacka. A. Bakhai.

85 AHA (American Heart Association) - 2011: Abstract: Poster Presentation. Treatment, costs, and 12-month outcomes stratified by GRACE risk score in patients with acute coronary syndrome undergoing percutaneous coronary intervention .Mohacsi, Iniguez, James, Ferrieres, Pavlides, Sartral, Belger, Tomlin, Norrbacka

86 ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - 2011: Abstract: Poster Presentation. Treatment, costs, and 12-month outcomes stratified by GRACE risk score in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Mohacsi, Iniguez, James, Ferrieres, Pavlides, Sartral, Belger, Tomlin, Norrbacka.

2012

87 Manuscript in Journal of Interventional Cardiology (JOIC) - Impact Factor 1.5. Clinical

Outcomes, Resource Use, and Costs at 1 Year in Patients with Acute Coronary Syndrome Undergoing PCI: Results from the Multinational APTOR Registry. J Interven Cardiol 2012; 25:19–27. Ameet Bakhai, Jean Ferrieres, Andres Iñiguez, Magali Sartral, Mark Belger, Claude Schmitt, Uwe Zeymer,on Behalf of APTOR Trial Investigators.

88 Manuscript in Archives of Cardiovascular Diseases - Impact Factor: 1.662. Risk of cardiovascular and bleeding events and mortality in patients with chronic kidney disease and acute coronary syndrome undergoing percutaneous coronary intervention: the APTOR-II study Supplements 01/2012; 4(1):1. DOI: 10.1016/S1878-6480(12)70397. Jean Ferrières, Guy Berkenboom, Zdenek Coufal, Stefan James, Attila MoháCsi, Gregory Pavlides, Kirsi Norrbacka, Magali Sartral, Marie-Ange Paget, Molly Tomlin, Uwe Zeymer.

89 Supplement in “Progrès en Urologie” - June 2012 - Supplement 1: Uro-erectal dysfunction: a new nosologic entity? Scientific coordination. M. Rouprêt, T. Seisen, A. Faix, S. Droupy, P. Costa, F. Giuliano, A ; De La Taille, F. Desgrandchamps, JL Gallais (CRS Coaching)

90 European Respiratory Society - 2012: Abstract: Poster Presentation. Patients’, Relatives’, and Practitioners’ Views on Pulmonary Arterial Hypertension. Olivier Sitbon, Sophie Alami, Luc Mouthon, Vincent Cottin, Dominique Desjeux, Esther Quessette (Lilly), Serge Poiraudeau (ML Coaching)

December 2016

91 Manuscript in « Progrès en Urologie » - Impact Factor: 0.801: Effects of Phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia – Effets des inhibiteurs de la phosphodiesterase de type 5 sur les symptômes du bas appareil urinaire associés à une hypertrophie bénigne de la prostate. Nov. 2012 http://dx.doi.org/10.1016/j.purol.2012.11.009. François Giuliano, Morgan Rouprêt, Gabriel Doridot (Lilly), Alexandre de La Taille (CRS Coaching)

92 Supplement in “Progrès en Urologie” - November 2012 - Supplement 13: 106th French Congress of Urology Paris - Pages 741 to 860 (CRS Coaching).

2013

93 Manuscript in Postgraduate Medicine Journal - Impact Factor: 1.972 - On line

DOI:10.3810/pgm.2013.03.2644 Treatment, Outcomes, Costs, and Quality of Life of Women and Men with Acute Coronary Syndromes after Percutaneous Coronary Intervention (PCI): Results from the Antiplatelet Therapy Observational Registry Ameet Bakhai, Jean Ferrieres, Stefan James, Andres Iniguez, Attila Mohacsi, Gregory Pavlides, Mark Belger, Krisi Norrbacka, Magali Sartral.

94 Manuscript in International Journal of Cardiology - Impact Factor: 7.08 - Predictors, Cost, and Outcomes of Patients with Acute Coronary Syndrome who Receive Optimal Secondary Prevention Therapy: Results from the Antiplatelet Treatment Observational Registries (APTOR) International Journal of Cardiology. 2013;170:239-45. Zeymer U, Berkenboom G, Coufal Z, Belger M, Sartral M, Norrbacka K, Bakhai A, on Behalf of APTOR Investigators

95 French Congress of Urology - Abstract - Oral presentation – 21 November 2013 - Regards croisés des patients et des médecins sur la perception des pratiques de prise en charge de la Dysfonction Erectile (DE) et des troubles urinaires du bas appareil (TUBA) liés à une Hypertrophie Bénigne de la Prostate (HBP): Résultats d’une enquête menée en novembre 2011. Thierry Lebret, Karim Hamidi, Patrick Coloby (Team Coaching)

2014

96 Manuscript - ongoing writing – Tadalafil effect on LUTS irritative symptoms and quality of life. M. Roupret, A. De La Taille, G. Doridot (CRS Coaching)

97 Manuscript in Archives of Cardiovascular Diseases - Impact Factor: 1.662 - Available online 11 March 2014 – REVIEW - New antiplatelet agents in the treatment of Acute Coronary Syndromes. Archives of Cardiovascular Disease (2014) 107, 178-187. http://dx.doi.org/10.1016/j.acvd.2014.01.009. Pierre Sabouret, Magali Taiel-Sartral.

98 Manuscript in Journal of Clinical & Experimental Cardiology - Impact Factor: 2.029 - Accepted 31 July 2014 - Ref.: Ms. No. CLINICALGROUP-14-554R - Antiplatelet agents in diabetic patients: clinical advances and remaining questions. Pierre Sabouret, Magali Taiel-Sartral, Jean-Philippe Kevorkian, Bruno Vergès.

2015

99 Manuscript in “Progrès en Urologie” - Impact Factor: 0.801 – Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia Sexual effects of medications for LUTS secondary to BPH. Prog Urol. 2015 25, 115—127. A. Descazeaud, A. de La Taille, F. Giuliano, F. Desgrandchamps, G. Doridot (CRS Coaching).

2016

100 Manuscript in Clinical Cardiology - Impact Factor: 2.59 - 18th of April - Manuscript number: AID CLC22553 - Prasugrel use in “real life”: A Report from outpatient setting in France. Clin Cardiol. 2016 Jun 14. doi: 10.1002/clc.22553. [Epub ahead of print] PMID: 27299993 [PubMed - as supplied by publisher]. Pierre Sabouret, Magali Taiel-Sartral, Florence Chartier, Sabine Akiki, Thomas Cuisset

101 European Days of the French Society of Cardiology (JESFC) - Abstract - Oral Presentation: Prasugrel use in “real life”: Report from outpatient settings in France - Pierre Sabouret, Thomas Cuisset.

December 2016